구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Vedolizumab |
Overview Company | Takeda |
Overview Modality | ANTIBODY |
Overview Target | Colitis |
Overview Indication | Ulcerative Colitis and Crohn's Disease |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | Novel therapeutic avenues, including TYK2 and HDAC inhibitors, as well as nanotechnology-based delivery systems, show encoura |
Positioning Known limitation | resistance to VDZ in UC |
MoA Mechanism | checkpoint inhibitor-induced colitis: a case report |
MoA Biomarker | biomarkers were evaluated |
PK/PD Half-life | 26 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | pneumonitis and myocarditis |
Toxicology CRS | Reported |
Clinical Safety signal | pneumonitis and myocarditis |
Clinical Result source | ClinicalTrials.gov NCT02461758 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02461758 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Vedolizumab |
Overview Company | Takeda |
Overview Modality | ANTIBODY |
Overview Target | Colitis |
Overview Indication | Ulcerative Colitis and Crohn's Disease |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | Novel therapeutic avenues, including TYK2 and HDAC inhibitors, as well as nanotechnology-based delivery systems, show encoura |
Positioning Known limitation | resistance to VDZ in UC |
MoA Mechanism | checkpoint inhibitor-induced colitis: a case report |
MoA Biomarker | biomarkers were evaluated |
PK/PD Half-life | 26 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | pneumonitis and myocarditis |
Toxicology CRS | Reported |
Clinical Safety signal | pneumonitis and myocarditis |
Clinical Result source | ClinicalTrials.gov NCT02461758 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02461758 |
추천 비교
추천 비교